Shots:

• Denali reported the results of P-Ib studies of DNL747 in AD and ALS and provides an update on its broad RIPK1 program including DNL788 and DNL758. The P-Ib studies has met its safety endpoints in patients with ALS and AD- further dose escalation to achieve higher levels of target inhibition may be limited by preclinical chronic safety data
• The two companies will pause the clinical studies of DNL747 and focus on accelerating development of DNL788 in neurological indications- with a plan to initiate its clinical testing by early 2021
• Sanofi has completed P-I study of DNL758 in healthy volunteer and is planning further clinical studies in multiple indications following the P-I data

Click here to read full press release/ article | Ref: Buinesswire | Image: Pharmaworld